Abstract:Adoptive T-cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs) and T cells gene-modified to express either a T cell receptor (TCR) or a chimeric antigen receptor (CAR), have demonstrated clinical efficacy for a proportion of patients and cancer-types. The field of ACT has been driven forward by the clinical success of CD19-CAR therapy against various advanced B-cell malignancies, including curative responses for some leukemia patients. However, relapse remains problematic, in particular for lymphoma. Moreover, for a variety of reasons, relative limited efficacy has been demonstrated for ACT of non-hematological solid tumors. Indeed, in addition to pre-infusion challenges including lymphocyte collection and manufacturing, ACT failure can be attributed to several biological processes post-transfer including, (i) inefficient tumor trafficking, infiltration, expansion and retention, (ii) chronic antigen exposure coupled with insufficient costimulation resulting in T-cell exhaustion, (iii) a range of barriers in the tumor microenvironment (TME) mediated by both tumor cells and suppressive immune infiltrate, (iv) tumor antigen heterogeneity and loss, or down-regulation of antigen presentation machinery, (v) gain of tumor intrinsic mechanisms of resistance such as to apoptosis, and (vi) various forms of toxicity and other adverse events in patients. Affinity-optimized TCRs can improve T-cell function and innovative CAR designs as well as gene-modification strategies can be used to coengineer specificity, safety, and function into T cells. Coengineering strategies can be designed not only to directly support the transferred T cells, but also to block suppressive barriers in the TME and harness endogenous innate and adaptive immunity. Here, we review a selection of the remarkable T-cell coengineering strategies, including of tools, receptors, and gene-cargo, that have been developed in recent years to augment tumor control by ACT, more and more of which are advancing to the clinic.

Particle-Based Artificial Antigen-Presenting Cell Systems for T Cell Activation in Adoptive T Cell Therapy

Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells

Human cell-based artificial antigen-presenting cells for cancer immunotherapy

Microfluidic-based preparation of artificial antigen-presenting gel droplets for integrated and minimalistic adoptive cell therapy strategies

Alginate-based artificial antigen presenting cells expand functional CD8+ T cells with memory characteristics for adoptive cell therapy

An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in Ex Vivo and in Vivo Murine Melanoma Models.

A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.

A general pHLA-CD80 scaffold fusion protein to promote efficient antigen-specific T cell-based immunotherapy

Engineering Nanoscale Artificial Antigen-Presenting Cells By Metabolic Dendritic Cell Labeling To Potentiate Cancer Immunotherapy

Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation

Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells

Size-transformable antigen-presenting cell-mimicking nanovesicles potentiate effective cancer immunotherapy.

Delivery Systems Developed for Treatment Combinations to Improve Adoptive Cell Therapy

The Pluripotent Path to Immunotherapy

Surface‐Functionalized Microgels as Artificial Antigen‐Presenting Cells to Regulate Expansion of T Cells

Artificial Antigen-Presenting Cell Topology Dictates T Cell Activation

Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens

Adoptive immunotherapy for cancer: harnessing the T cell response

Biomimetic Magnetosomes As Versatile Artificial Antigen-Presenting Cells to Potentiate T-Cell-Based Anticancer Therapy

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Coengineering specificity, safety, and function into T cells for cancer immunotherapy